1139 related articles for article (PubMed ID: 29166338)
1. Use of Organs From Hepatitis C Virus-Positive Donors for Uninfected Recipients: A Potential Cost-Effective Approach to Save Lives?
Trotter PB; Summers DM; Ushiro-Lumb I; Robb M; Bradley JA; Powell J; Watson CJE; Neuberger J
Transplantation; 2018 Apr; 102(4):664-672. PubMed ID: 29166338
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of hepatitis C-positive donor kidney transplantation for hepatitis C-negative recipients with concomitant direct-acting antiviral therapy.
Gupta G; Zhang Y; Carroll NV; Sterling RK
Am J Transplant; 2018 Oct; 18(10):2496-2505. PubMed ID: 30075489
[TBL] [Abstract][Full Text] [Related]
3. Liver Transplant From Increased-Risk Donors in the Era of Direct-Acting Antivirals for Hepatitis C.
Shaikh OS; Rogal S; Malik A; Sharma V; Cacciarelli T
Exp Clin Transplant; 2020 Oct; 18(5):605-611. PubMed ID: 31324136
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of using kidneys from hepatitis C nucleic acid test-positive donors for transplantation in hepatitis C-negative recipients.
Kadatz M; Klarenbach S; Gill J; Gill JS
Am J Transplant; 2018 Oct; 18(10):2457-2464. PubMed ID: 29797402
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients.
Eckman MH; Woodle ES; Thakar CV; Alloway RR; Sherman KE
Am J Kidney Dis; 2020 Jun; 75(6):857-867. PubMed ID: 32081494
[TBL] [Abstract][Full Text] [Related]
6. Short-term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct-acting antivirals.
La Hoz RM; Sandıkçı B; Ariyamuthu VK; Tanriover B
Am J Transplant; 2019 Nov; 19(11):3058-3070. PubMed ID: 31207073
[TBL] [Abstract][Full Text] [Related]
7. Successful heart-kidney transplantation from a Hepatitis C viremic donor to negative recipient: One year of follow-up.
Wettersten N; Tran H; Mekeel K; Pretorius V; Adler E; Aslam S
Transpl Infect Dis; 2019 Feb; 21(1):e13002. PubMed ID: 30222242
[TBL] [Abstract][Full Text] [Related]
8. The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes.
Axelrod DA; Schnitzler MA; Alhamad T; Gordon F; Bloom RD; Hess GP; Xiao H; Nazzal M; Segev DL; Dharnidharka VR; Naik AS; Lam NN; Ouseph R; Kasiske BL; Durand CM; Lentine KL
Am J Transplant; 2018 Oct; 18(10):2473-2482. PubMed ID: 29701909
[TBL] [Abstract][Full Text] [Related]
9. Changes in Utilization and Discard of HCV Antibody-Positive Deceased Donor Kidneys in the Era of Direct-Acting Antiviral Therapy.
Bowring MG; Kucirka LM; Massie AB; Ishaque T; Bae S; Shaffer AA; Garonzik Wang J; Sulkowski M; Desai N; Segev DL; Durand CM
Transplantation; 2018 Dec; 102(12):2088-2095. PubMed ID: 29912046
[TBL] [Abstract][Full Text] [Related]
10. Current Use of Hearts From Hepatitis C Viremic Donors.
Moayedi Y; Fan CPS; Gulamhusein AF; Manlhiot C; Ross HJ; Teuteberg JJ; Khush KK
Circ Heart Fail; 2018 Dec; 11(12):e005276. PubMed ID: 30562093
[TBL] [Abstract][Full Text] [Related]
11. Pros and Cons: Usage of organs from donors infected with hepatitis C virus - Revision in the direct-acting antiviral era.
Coilly A; Samuel D
J Hepatol; 2016 Jan; 64(1):226-31. PubMed ID: 26375245
[TBL] [Abstract][Full Text] [Related]
12. Kidney Transplant Program at the Mayo Clinic in Arizona.
Heilman RL; Khamash HA; Huskey JL; Chakkera HA; Batra RK; Katariya NN; Singer AL; Mathur AK; Moss AA; Reddy KS
Clin Transpl; 2014; ():61-8. PubMed ID: 26281128
[TBL] [Abstract][Full Text] [Related]
13. Liver Transplantation of HCV-viremic Donors Into HCV-negative Recipients in the United States: Increasing Frequency With Profound Geographic Variation.
Cotter TG; Aronsohn A; Reddy KG; Charlton M
Transplantation; 2021 Jun; 105(6):1285-1290. PubMed ID: 32639400
[TBL] [Abstract][Full Text] [Related]
14. The UNOS Renal Transplant Registry: Review of the Last Decade.
Andre M; Huang E; Everly M; Bunnapradist S
Clin Transpl; 2014; ():1-12. PubMed ID: 26281122
[TBL] [Abstract][Full Text] [Related]
15. Deceased Donor Kidney Transplantation in Taiwan in 2015.
Lee PC; Chiang YJ; Chen ST
Clin Transpl; 2014; ():55-9. PubMed ID: 26281127
[TBL] [Abstract][Full Text] [Related]
16. Utilizing increased risk for disease transmission (IRD) kidneys for pediatric renal transplant recipients.
Hwang CS; Gattineni J; MacConmara M
Pediatr Nephrol; 2019 Oct; 34(10):1743-1751. PubMed ID: 31243535
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
Shah AP; Cameron A; Singh P; Frank AM; Fenkel JM
Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28060446
[TBL] [Abstract][Full Text] [Related]
18. Mortality and Kidney Transplantation Outcomes Among Hepatitis C Virus-Seropositive Maintenance Dialysis Patients: A Retrospective Cohort Study.
Sawinski D; Forde KA; Lo Re V; Goldberg DS; Cohen JB; Locke JE; Bloom RD; Brensinger C; Weldon J; Shults J; Reese PP
Am J Kidney Dis; 2019 Jun; 73(6):815-826. PubMed ID: 30704882
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor.
Stepanova M; Sayiner M; de Avila L; Younoszai Z; Racila A; Younossi ZM
BMC Gastroenterol; 2016 Nov; 16(1):137. PubMed ID: 27846801
[TBL] [Abstract][Full Text] [Related]
20. Pre- Versus Posttransplant Treatment of Hepatitis C Virus With Direct-Acting Antivirals in Liver Transplant Recipients: More Issues to be Solved.
Abdelqader A; Kabacam G; Woreta TA; Hamilton JP; Luu H; Al Khalloufi K; Saberi B; Philosophe B; Cameron AM; Gurakar A
Exp Clin Transplant; 2017 Feb; 15(Suppl 1):1-5. PubMed ID: 28260422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
